Clinical research organization Veristat has partnered with Clene Nanomedicine to accelerate data outputs for clinical trial processes.
Veristat’s automated program allowed Clene to cut delivery time of biostatistical outputs for its drug application submission by 80%, according to the company.
Nearly a year ago, Clene submitted its lead asset, CNM-Au8, an oral gold nanocrystal suspension being developed for the treatment of amyotrophic lateral sclerosis (ALS), for FDA approval. The Salt Lake City-headquartered company based this decision on positive phase 2 data back in 2023, showing that the drug improved survival for ALS patients, despite missing the primary endpoint.
Veristat’s InStat program, launched in May, was designed as a zero-code, fully automated biostatistics solution to reduce manual effort. The goal of the program is to speed up time to approval with every output backed by validated statistical engines and expert biostatistician review.
“InStat is a modern solution built off a foundation of two decades of proven biostatistical analysis. We intentionally put AI where it adds speed, not where it adds risk: assisting biostatisticians in translating analytical intent into precise specifications,” Kyle McBride, Veristat’s vice president, AI & innovation, said in the release. “Once that's right, everything downstream is trustworthy.”
Clene is the first clinical trial sponsor to deliver data outputs with Veristat’s platform, The company was able to generate tables, listings and figures for its biomarker analysis using InStat in just one week, compared to six weeks.
“Veristat is re-engineering how complex biostatistical work gets done in clinical research,” McBride added.